IS6531A - Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það - Google Patents

Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það

Info

Publication number
IS6531A
IS6531A IS6531A IS6531A IS6531A IS 6531 A IS6531 A IS 6531A IS 6531 A IS6531 A IS 6531A IS 6531 A IS6531 A IS 6531A IS 6531 A IS6531 A IS 6531A
Authority
IS
Iceland
Prior art keywords
clariodorphysin
oxymorphic
clariforomycin
intermediates
essentially
Prior art date
Application number
IS6531A
Other languages
English (en)
Icelandic (is)
Inventor
Avrutov Ilya
Lifshitz Igor
Lewiner Elizabeth
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS6531A publication Critical patent/IS6531A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6531A 2000-02-29 2002-08-28 Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það IS6531A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18588800P 2000-02-29 2000-02-29
US18912000P 2000-03-14 2000-03-14
US21323900P 2000-06-22 2000-06-22
PCT/US2000/033843 WO2001064224A1 (en) 2000-02-29 2000-12-15 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
IS6531A true IS6531A (is) 2002-08-28

Family

ID=27392028

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6531A IS6531A (is) 2000-02-29 2002-08-28 Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það

Country Status (15)

Country Link
US (3) US6617436B2 (enExample)
EP (1) EP1313486A1 (enExample)
JP (1) JP2004509062A (enExample)
KR (1) KR20030047873A (enExample)
AU (2) AU2001225787C1 (enExample)
CA (1) CA2401571A1 (enExample)
CZ (1) CZ20023167A3 (enExample)
HR (1) HRP20020709A2 (enExample)
HU (1) HUP0302466A2 (enExample)
IL (1) IL151496A0 (enExample)
IS (1) IS6531A (enExample)
PL (1) PL366021A1 (enExample)
SK (1) SK13722002A3 (enExample)
WO (1) WO2001064224A1 (enExample)
YU (1) YU64202A (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217951C (zh) * 1999-12-16 2005-09-07 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物iv
AU2001222619C1 (en) * 2000-01-11 2006-01-12 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
YU64202A (sh) * 2000-02-29 2005-03-15 Teva Pharmaceutical Industries Ltd. Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
CN102417532A (zh) * 2011-12-20 2012-04-18 浙江国邦药业有限公司 一种泰利霉素关键中间体5-德胺糖基-6-o-甲基红霉素的合成方法
CN102718821B (zh) * 2012-06-27 2014-12-03 浙江国邦药业有限公司 一种克拉霉素合成过程中甲基化反应以及甲基化试剂的回收套用方法
CN103880901A (zh) * 2012-12-23 2014-06-25 菏泽市方明制药有限公司 一种克拉霉素中间甲化物的制备方法
CN106905204B (zh) * 2017-02-24 2018-07-20 杭州新桂实业有限公司 一种克拉霉素合成过程中甲基化反应溶剂的回收套用方法
CN108117573A (zh) * 2017-12-26 2018-06-05 宁夏启元药业有限公司 4"-o-（三甲基硅）红霉素a 9-o-（1-乙氧基-1-甲基乙基）肟的合成方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669236A (en) * 1900-02-16 1901-03-05 Frank M Garland Automatic machine-gun.
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
DE3174858D1 (en) * 1980-12-25 1986-07-24 Fujitsu Ltd Nonvolatile semiconductor memory device
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
TW276996B (enExample) * 1992-04-24 1996-06-01 Astra Ab
EP0650353B1 (en) * 1992-06-04 2002-05-22 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
IL127833A (en) 1996-07-29 2004-06-20 Abbott Lab Preparation of the crystalline form II of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
DE19950781A1 (de) * 1999-10-21 2001-04-26 Knoll Ag Mehrteiliges Etikett für Durchdrückpackungen, seine Herstellung und Verwendung
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
CN1217951C (zh) * 1999-12-16 2005-09-07 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物iv
AU2001222619C1 (en) * 2000-01-11 2006-01-12 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
YU64202A (sh) * 2000-02-29 2005-03-15 Teva Pharmaceutical Industries Ltd. Postupak za pripremanje klaritromicina i intermedijera klaritromicina, klaritromicina u osnovi bez oksima i farmaceutskog preparata koji ga sadrži
HUP0300418A3 (en) * 2000-03-15 2003-09-29 Hanmi Pharm Co Ltd Hwaseong Gu Method of preparing clarithromycin of form ii crystals
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
IN192748B (enExample) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
ES2195727B1 (es) * 2001-07-05 2005-03-01 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US20050163857A1 (en) * 2002-04-03 2005-07-28 Ashok Rampal Clarithromycin formulations having improved bioavailability
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics

Also Published As

Publication number Publication date
HUP0302466A2 (hu) 2003-11-28
SK13722002A3 (sk) 2003-08-05
JP2004509062A (ja) 2004-03-25
CA2401571A1 (en) 2001-09-07
AU2001225787C1 (en) 2006-09-21
AU2001225787B2 (en) 2005-12-08
US20060205683A1 (en) 2006-09-14
AU2578701A (en) 2001-09-12
EP1313486A1 (en) 2003-05-28
IL151496A0 (en) 2003-04-10
CZ20023167A3 (cs) 2003-10-15
US20030216556A1 (en) 2003-11-20
US6617436B2 (en) 2003-09-09
US20010037015A1 (en) 2001-11-01
KR20030047873A (ko) 2003-06-18
HRP20020709A2 (en) 2004-12-31
YU64202A (sh) 2005-03-15
PL366021A1 (en) 2005-01-24
US7101858B2 (en) 2006-09-05
WO2001064224A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
IS6531A (is) Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
NO20032332D0 (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
MXPA03006260A (es) Derivados de amina sustituidos y metodos de uso.
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
MXPA03006010A (es) Derivados de arilamina sustituida y metodos de uso.
ITMI20010602A0 (it) Procedimento per la preparazione di talopram puro
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
IS2821B (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
EP1261623A4 (en) RETINOL DERIVATIVES, METHOD OF ITS PRESENTATIONS AND THEIR USES
NO20013735L (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
ITMI20000050A0 (it) Procedimento per la preparazione della 5-carbossiftalide
ITMI20000681A0 (it) Procedimento per la preparazione di miscele di metilendianilina e suoi omologhi superiori
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
AU5881001A (en) Method of stabilizing preparation
DK1241169T3 (da) Isoindoloindolonforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO20030587D0 (no) Fremgangsmåte til fremstilling av diskodermolid og analoger derav
AUPQ599500A0 (en) Novel peptides, modulatory agents therefor and methods of using them
DK1259523T3 (da) Pluraflaviner og derivater deraf, fremgangsmåde til fremstilling og anvendelse deraf
ZA200001843B (en) Preparation of standard gas mixtures.